CREATIVE SCIENTIST, INC.

Medtech

High-throughput screening platform using human endothelial cells (ECFCs) and proprietary growth media (Vecstem) to evaluate VEGFR signaling inhibition and identify toxicological effects of drugs and c

Grants
$499K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · New Endothelial Cell-Based Assay to Assess Variability of Nitric Oxide Production in Humans$224,460
Federal grantDepartment of Health and Human Services · Phase I · New Endothelial Cell-Based Assay to Assess Variability of Nitric Oxide Production in Humans$50,000
Federal grantDepartment of Health and Human Services · Phase I · A New Assay Platform to Screen for Chemicals Adversely Affecting VEGFR Signaling in Endothelial Cells$224,700
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1935QUINTERO & KONTOPOULOS PLLC——
1936INNOVATIVE DIAGNOSTICS, INC.——
1937FLUIDISPEC LLC——
1938CREATIVE SCIENTIST, INC.——
1939Cutting Edge Spine, llc—$1.3M
1940REFLEXION MEDICAL, INC.—$413M
1941Conformal Medical, Inc.—$145M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.